Clearside Biomedical, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- George Lasezkay
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 900 North Point Parkway Alpharetta GA United States of America 30005
- IPO Date
- Jun 2, 2016
- CIK
- 0001539029
- Website
- clearsidebio.com
- Similar Companies
- Business
- Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the proprietary suprachoroidal space using its patented SCS Microinjector platform, which enables in-office, repeatable, non-surgical targeted administration to the macula, retina, and choroid for sight-threatening ocular diseases. The company offers XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, the first FDA-approved product for suprachoroidal administration indicated for macular edema associated with uveitis and available in the U.S. through commercial partner Bausch + Lomb; it develops CLS-AX (axitinib injectable suspension) for suprachoroidal injection, which completed Phase 2b trials for wet age-related macular degeneration (wet AMD) and is Phase 3-ready; and pursues preclinical programs including small molecules for geographic atrophy and combinations such as steroid plus tyrosine kinase inhibitor for diabetic macular edema. Clearside maintains five strategic licensing collaborations for its SCS platform with Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, REGENXBIO (with global partner AbbVie), and Arctic Vision (with commercial partner Santen), supporting commercial products and late-stage clinical programs in gene therapies and anti-tumor agents across retinal diseases. In July 2025, Clearside announced exploration of strategic alternatives including potential sale of its business to advance the SCS platform amid market challenges, transitioning employees to consulting roles and pausing internal R&D; in November 2024, partner Arctic Vision entered a commercialization deal with Santen. Founded in 2011 and headquartered in Alpharetta, Georgia, Clearside operates primarily in the U.S. with global partnerships targeting patients with retinal conditions such as uveitis, wet AMD, and diabetic macular edema.
Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Hold” from Brokerages
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates